Funding stage: Series A (1 M EUR - < 5 M EUR) Founded: 2017 Employees: From 1 to 5
Business model: Other types of licence Target: Business
GlyCardial Diagnostics is developing Apo J-Glyc as a novel biomarker for the diagnosis and prognosis of myocardial ischemia.
Minority stake unknown %
Investors: CAIXA CAPITAL RISC, HEALTHEQUITY SCR
Source: Press releases , newsletters & platforms , company websites , annual reports & accounts , regulatory body sites & stock exchanges
We are continually updating our list of new startups so please let us know if you have recently started one.